Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 18, Pages 4547
Publisher
MDPI AG
Online
2021-09-10
DOI
10.3390/cancers13184547
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of Preoperative Circulating Tumor DNA Status on Survival Outcomes After Hepatectomy for Resectable Colorectal Liver Metastases
- (2021) Shin Kobayashi et al. ANNALS OF SURGICAL ONCOLOGY
- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer
- (2021) Timothy J. Iveson et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
- (2021) Mary B. Daly et al. Journal of the National Comprehensive Cancer Network
- Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy
- (2021) Shengnan Jin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Preoperative detection of KRAS mutated circulating tumor DNA is an independent risk factor for recurrence in colorectal cancer
- (2021) Yuki Nakamura et al. Scientific Reports
- ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm
- (2021) Mahendra Naidoo et al. Cancers
- The Feasibility of Patient-Specific Circulating Tumor DNA Monitoring throughout Multi-Modality Therapy for Locally Advanced Esophageal and Rectal Cancer: A Potential Biomarker for Early Detection of Subclinical Disease
- (2021) Christopher Boniface et al. Diagnostics
- Liquid Biopsy Cell-free DNA Biomarkers in Patients With Oligometastatic Colorectal Cancer Treated by Ablative Radiotherapy
- (2021) MASAKI NAKAMURA et al. ANTICANCER RESEARCH
- Use of Molecular Assays and Circulating Tumor DNA in Early Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group ( GICTEG )
- (2021) Arturo Loaiza‐Bonilla et al. ONCOLOGIST
- CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer
- (2021) Hiroya Taniguchi et al. CANCER SCIENCE
- Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial
- (2021) Joana Vidal et al. CLINICAL CANCER RESEARCH
- Minimal Residual Disease Detection using a Plasma-Only Circulating Tumor DNA Assay in Colorectal Cancer Patients
- (2021) Aparna R. Parikh et al. CLINICAL CANCER RESEARCH
- Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival
- (2021) Anders Jakobsen et al. EUROPEAN JOURNAL OF CANCER
- Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer
- (2021) Gong Chen et al. Journal of Hematology & Oncology
- Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
- (2021) Thierry Conroy et al. LANCET ONCOLOGY
- Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment
- (2021) Brice Pastor et al. Molecular Oncology
- Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study
- (2021) Jeanne Tie et al. PLOS MEDICINE
- Clinical Implication of Liquid Biopsy in Colorectal Cancer Patients Treated with Metastasectomy
- (2021) Soohyeon Lee et al. Cancers
- O-11 Monitoring molecular residual disease by circulating tumor DNA in resectable colorectal cancer: Molecular subgroup analyses of a prospective observational study GALAXY in CIRCULATE-Japan
- (2021) H. Shirasu et al. ANNALS OF ONCOLOGY
- True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature
- (2021) Chiara Nicolazzo et al. CANCER LETTERS
- Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial
- (2021) Julien Taieb et al. CLINICAL CANCER RESEARCH
- Survival and organ preservation according to clinical response after total neoadjuvant therapy in locally advanced rectal cancer patients: A secondary analysis from the organ preservation in rectal adenocarcinoma (OPRA) trial.
- (2021) Hannah Thompson et al. JOURNAL OF CLINICAL ONCOLOGY
- Content of circulating tumor DNA depends on the tumor type and the dynamics of tumor size, but is not influenced significantly by physical exercise, time of the day or recent meal
- (2021) Ekaterina S. Kuligina et al. Cancer Genetics
- PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer
- (2021) Alexander Stein et al. Journal for ImmunoTherapy of Cancer
- Circulating epigenetic biomarkers for detection of recurrent colorectal cancer
- (2020) Erin L. Symonds et al. CANCER
- Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial
- (2020) John A Bridgewater et al. LANCET ONCOLOGY
- Perioperative Circulating Tumor DNA in Colorectal Liver Metastases: Concordance with Metastatic Tissue and Predictive Value for Tumor Burden and Prognosis
- (2020) Yiping He et al. Cancer Management and Research
- Disease Monitoring Using Post-Induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer
- (2020) Xiaoju Max Ma et al. CLINICAL CANCER RESEARCH
- Utility of circulating tumor cells and DNA in the management of advanced colorectal cancer
- (2020) Xiaohong Pan et al. Future Oncology
- Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy
- (2020) Takeshi Yamada et al. International Journal of Clinical Oncology
- Cross-sectional analysis of circulating tumor DNA in primary colorectal cancer at surgery and during post-surgery follow-up by liquid biopsy
- (2020) Matteo Allegretti et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients with Elevated CEA
- (2020) Pat Gulhati et al. JNCI-Journal of the National Cancer Institute
- The effect of surgical trauma on circulating free DNA levels in cancer patients – implications for studies of circulating tumor DNA
- (2020) Tenna V. Henriksen et al. Molecular Oncology
- Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer
- (2020) Chongkai Wang et al. ONCOLOGIST
- Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing
- (2020) Jun-Kyu Kang et al. PLoS One
- Circulating Tumor DNA Is Capable of Monitoring the Therapeutic Response and Resistance in Advanced Colorectal Cancer Patients Undergoing Combined Target and Chemotherapy
- (2020) Hua Cao et al. Frontiers in Oncology
- Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancer
- (2020) Anders K. Boysen et al. ACTA ONCOLOGICA
- Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
- (2020) G. Argiles et al. ANNALS OF ONCOLOGY
- Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence
- (2020) Satoshi Murahashi et al. BRITISH JOURNAL OF CANCER
- Plasma or Serum: Which Is Preferable for Mutation Detection in Liquid Biopsy?
- (2020) Fabio Pittella-Silva et al. CLINICAL CHEMISTRY
- A First Step to a Biomarker of Curative Surgery in Colorectal Cancer by Liquid Biopsy of Methylated Septin 9 Gene
- (2020) M. Leon Arellano et al. DISEASE MARKERS
- ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
- (2020) Arvind Dasari et al. Nature Reviews Clinical Oncology
- Watch and wait approach in rectal cancer: Current controversies and future directions
- (2020) Fernando López-Campos et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Circulating Tumor DNA as a Preoperative Marker of Recurrence in Patients with Peritoneal Metastases of Colorectal Cancer: A Clinical Feasibility Study
- (2020) Jamie J. Beagan et al. Journal of Clinical Medicine
- Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer
- (2020) Susanne Klein-Scory et al. Frontiers in Oncology
- Monitoring of Early Changes of Circulating Tumor DNA in the Plasma of Rectal Cancer Patients Receiving Neoadjuvant Concomitant Chemoradiotherapy: Evaluation for Prognosis and Prediction of Therapeutic Response
- (2020) Filip Pazdirek et al. Frontiers in Oncology
- Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients
- (2020) Xiaojing Xu et al. BMC CANCER
- Evaluation of Circulating Tumor DNA for Methylated BCAT1 and IKZF1 to Detect Recurrence of Stage II/Stage III Colorectal Cancer (CRC)
- (2020) Benjamin L. Musher et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer
- (2020) Donghui Zou et al. CARCINOGENESIS
- Serial circulating tumor DNA in predicting and monitoring the effect of neoadjuvant chemoradiotherapy in patients with rectal cancer: a prospective multicenter study
- (2020) Jiaolin Zhou et al. CLINICAL CANCER RESEARCH
- A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study
- (2020) Matthias Unseld et al. INTERNATIONAL JOURNAL OF CANCER
- Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies
- (2020) Jeanne Tie et al. INTERNATIONAL JOURNAL OF CANCER
- Detection of circulating tumor DNA in patients of operative colorectal and gastric cancers
- (2020) Takeyuki Suzuki et al. Oncotarget
- The Level of Preoperative Plasma KRAS Mutations and CEA Predict Survival of Patients Undergoing Surgery for Colorectal Cancer Liver Metastases
- (2020) Jiri Polivka et al. Cancers
- Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial
- (2020) Smiths S Lueong et al. CLINICAL CHEMISTRY
- Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials
- (2020) Thierry André et al. LANCET ONCOLOGY
- Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
- (2020) Renu R Bahadoer et al. LANCET ONCOLOGY
- Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing
- (2020) Matilda Holm et al. PLoS One
- Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer
- (2019) Giulia Siravegna et al. CLINICAL CANCER RESEARCH
- Peripheral Circulating Tumor DNA Detection Predicts Poor Outcomes After Liver Resection for Metastatic Colorectal Cancer
- (2019) Raja R. Narayan et al. ANNALS OF SURGICAL ONCOLOGY
- The role of mSEPT9 in screening, diagnosis, and recurrence monitoring of colorectal cancer
- (2019) Jie Sun et al. BMC CANCER
- Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic Response
- (2019) Ning Jia et al. Frontiers in Genetics
- Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer
- (2019) Yuxuan Wang et al. JAMA Oncology
- Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
- (2019) Thomas Reinert et al. JAMA Oncology
- Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial
- (2019) Bidard et al. Cells
- Genomic profiling of blood-derived circulating tumor DNA from patients with colorectal cancer: Implications for response and resistance to targeted therapeutics
- (2019) In Sil Choi et al. MOLECULAR CANCER THERAPEUTICS
- Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS ‐mutant metastatic colorectal cancer
- (2019) Elena Elez et al. Molecular Oncology
- RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer
- (2019) Erik J. van Helden et al. Molecular Oncology
- Prognostic Value of Serum NPY Hypermethylation in Neoadjuvant Chemoradiotherapy for Rectal Cancer
- (2019) Ane L. Appelt et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Dynamic monitoring of HER2 amplification in circulating DNA of patients with metastatic colorectal cancer treated with cetuximab
- (2019) R. Liu et al. Clinical & Translational Oncology
- Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer
- (2019) Emilie Moati et al. INTERNATIONAL JOURNAL OF CANCER
- Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer
- (2019) N Tarazona et al. ANNALS OF ONCOLOGY
- Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer
- (2019) Iben Lyskjær et al. Scientific Reports
- Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer
- (2019) Hiroki Osumi et al. Scientific Reports
- Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
- (2019) Jeanne Tie et al. JAMA Oncology
- NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer
- (2019) Lars Henrik Jensen et al. Cancers
- MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer
- (2019) Shelize Khakoo et al. CLINICAL CANCER RESEARCH
- Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction
- (2019) Jee-Soo Lee et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Therapeutic Monitoring of Circulating DNA Mutations in Metastatic Cancer with Personalized Digital PCR
- (2019) Christina M. Wood-Bouwens et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA
- (2019) Lucie Benešová et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Use of Liquid Biopsy in Monitoring Colorectal Cancer Progression Shows Strong Clinical Correlation
- (2018) Qiushi Sun et al. AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study
- (2018) J B Bachet et al. ANNALS OF ONCOLOGY
- Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival
- (2018) Joel M. Baumgartner et al. ANNALS OF SURGICAL ONCOLOGY
- Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study
- (2018) Julia Bergheim et al. BRITISH JOURNAL OF CANCER
- Mutation and Methylation Analysis of Circulating Tumor DNA Can Be Used for Follow-up of Metastatic Colorectal Cancer Patients
- (2018) Nele Boeckx et al. Clinical Colorectal Cancer
- Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer
- (2018) Bo Fu et al. DISEASE MARKERS
- Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study
- (2018) Jeanne Tie et al. GUT
- Effect of More vs Less Frequent Follow-up Testing on Overall and Colorectal Cancer–Specific Mortality in Patients With Stage II or III Colorectal Cancer
- (2018) Peer Wille-Jørgensen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival
- (2018) David H. Murray et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma
- (2018) C. B. Thomsen et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
- (2018) Al B. Benson et al. Journal of the National Comprehensive Cancer Network
- Targeted Sequencing of Circulating Tumor DNA to Monitor Genetic Variants and Therapeutic Response in Metastatic Colorectal Cancer
- (2018) Hung-Chih Hsu et al. MOLECULAR CANCER THERAPEUTICS
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- (2018) Axel Grothey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monitoring colorectal cancer following surgery using plasma circulating tumor DNA
- (2018) Xiao Sun et al. Oncology Letters
- Monitoring circulating tumor DNA revealed dynamic changes in KRAS status in patients with metastatic colorectal cancer
- (2018) Yuji Takayama et al. Oncotarget
- Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor
- (2018) Caroline Vandeputte et al. Oncotarget
- Circulating tumour DNA for monitoring colorectal cancer—a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection
- (2018) Erin L. Symonds et al. Clinical Epigenetics
- RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
- (2018) Jiannan Yao et al. Canadian Journal of Gastroenterology and Hepatology
- The blood mSEPT9 is capable of assessing the surgical therapeutic effect and the prognosis of colorectal cancer
- (2018) Lele Song et al. Biomarkers in Medicine
- Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
- (2018) C M Parseghian et al. ANNALS OF ONCOLOGY
- Circulating Free Methylated Tumor DNA Markers for Sensitive Assessment of Tumor Burden and Early Response Monitoring in Patients Receiving Systemic Chemotherapy for Colorectal Cancer Liver Metastasis
- (2018) Jagdeep Singh Bhangu et al. ANNALS OF SURGERY
- Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study
- (2018) Marc Peeters et al. CLINICAL CANCER RESEARCH
- Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan
- (2018) Chiara Cremolini et al. JAMA Oncology
- Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer
- (2017) Ludovic Barault et al. GUT
- Serial profiling of circulating tumor DNA for optimization of anti-VEGF chemotherapy in metastatic colorectal cancer patients
- (2017) Masami Yamauchi et al. INTERNATIONAL JOURNAL OF CANCER
- Methylated free-circulatingHPP1DNA is an early response marker in patients with metastatic colorectal cancer
- (2017) Andreas Herbst et al. INTERNATIONAL JOURNAL OF CANCER
- Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA
- (2017) Andreas W. Berger et al. PLoS One
- Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery
- (2017) Sarah B. Ng et al. Scientific Reports
- Utility ofKRASmutation detection using circulating cell-free DNA from patients with colorectal cancer
- (2016) Takeshi Yamada et al. CANCER SCIENCE
- Prediction of the efficacy of immunotherapy by measuring the integrity of cell-free DNA in plasma in colorectal cancer
- (2016) Masahiro Kitahara et al. CANCER SCIENCE
- Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
- (2016) Jeanne Tie et al. Science Translational Medicine
- Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
- (2016) D. S. Hong et al. Cancer Discovery
- Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab
- (2016) Rodrigo A. Toledo et al. Oncotarget
- A cross-sectional study comparing a blood test for methylatedBCAT1 and IKZF1tumor-derived DNA with CEA for detection of recurrent colorectal cancer
- (2016) Graeme P. Young et al. Cancer Medicine
- Impact ofRASandBRAFmutations on carcinoembryonic antigen production and pattern of colorectal metastases
- (2016) May Cho World Journal of Gastrointestinal Oncology
- Application of Circulating Tumor DNA as a Non-Invasive Tool for Monitoring the Progression of Colorectal Cancer
- (2016) Jiaolin Zhou et al. PLoS One
- Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
- (2015) M. P. Morelli et al. ANNALS OF ONCOLOGY
- Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer
- (2015) J. Tie et al. ANNALS OF ONCOLOGY
- A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma
- (2015) G. Rosati et al. ANNALS OF ONCOLOGY
- Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer
- (2015) David Sefrioui et al. DIGESTIVE AND LIVER DISEASE
- Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery
- (2015) Thomas Reinert et al. GUT
- Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib
- (2015) Andrea Wong et al. Journal of Translational Medicine
- High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study
- (2015) Ane L Appelt et al. LANCET ONCOLOGY
- Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation
- (2015) Paola Carpinetti et al. Oncotarget
- HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer
- (2015) Naoki Takegawa et al. Oncotarget
- Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform
- (2015) Evelyn Kidess et al. Oncotarget
- Circulating Free DNA as Biomarker and Source for Mutation Detection in Metastatic Colorectal Cancer
- (2015) Karen Lise Garm Spindler et al. PLoS One
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Clinical Relevance of Alterations in Quantity and Quality of Plasma DNA in Colorectal Cancer Patients: Based on the Mutation Spectra Detected in Primary Tumors
- (2014) Jen-Kou Lin et al. ANNALS OF SURGICAL ONCOLOGY
- Changes in mutational status during third-line treatment for metastatic colorectal cancer-Results of consecutive measurement of cell free DNA,KRASandBRAFin the plasma
- (2014) Karen-Lise Garm Spindler et al. INTERNATIONAL JOURNAL OF CANCER
- Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan
- (2012) K.-L. G. Spindler et al. CLINICAL CANCER RESEARCH
- Prognostic role of methylated free circulating DNA in colorectal cancer
- (2012) Alexander B. Philipp et al. INTERNATIONAL JOURNAL OF CANCER
- Circulating MACC1 Transcripts in Colorectal Cancer Patient Plasma Predict Metastasis and Prognosis
- (2012) Ulrike Stein et al. PLoS One
- Circulating Cell-Free DNA: A Promising Marker of Pathologic Tumor Response in Rectal Cancer Patients Receiving Preoperative Chemoradiotherapy
- (2011) Marco Agostini et al. ANNALS OF SURGICAL ONCOLOGY
- Prognostic Value of Circulating Mutant DNA in Unresectable Metastatic Colorectal Cancer
- (2010) Benoit Lefebure et al. ANNALS OF SURGERY
- Circulating mutant DNA to assess tumor dynamics
- (2008) Frank Diehl et al. NATURE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started